GB201710620D0 - Targeted protein degradation - Google Patents

Targeted protein degradation

Info

Publication number
GB201710620D0
GB201710620D0 GBGB1710620.4A GB201710620A GB201710620D0 GB 201710620 D0 GB201710620 D0 GB 201710620D0 GB 201710620 A GB201710620 A GB 201710620A GB 201710620 D0 GB201710620 D0 GB 201710620D0
Authority
GB
United Kingdom
Prior art keywords
protein degradation
targeted protein
targeted
degradation
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1710620.4A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to GBGB1710620.4A priority Critical patent/GB201710620D0/en
Publication of GB201710620D0 publication Critical patent/GB201710620D0/en
Priority to PCT/EP2018/067741 priority patent/WO2019007869A1/en
Priority to CA3068365A priority patent/CA3068365A1/en
Priority to US16/024,999 priority patent/US10683360B2/en
Priority to CN201880057133.9A priority patent/CN110997710A/zh
Priority to EP18735571.4A priority patent/EP3649149A1/en
Priority to BR112019028024-3A priority patent/BR112019028024A2/pt
Priority to GB1810814.2A priority patent/GB2568987A/en
Priority to JP2019572373A priority patent/JP7369039B2/ja
Priority to US16/879,896 priority patent/US11427643B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1710620.4A 2017-07-03 2017-07-03 Targeted protein degradation Ceased GB201710620D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
GBGB1710620.4A GB201710620D0 (en) 2017-07-03 2017-07-03 Targeted protein degradation
JP2019572373A JP7369039B2 (ja) 2017-07-03 2018-07-02 標的化タンパク質分解
CN201880057133.9A CN110997710A (zh) 2017-07-03 2018-07-02 靶向的蛋白降解
CA3068365A CA3068365A1 (en) 2017-07-03 2018-07-02 Targeted protein degradation
US16/024,999 US10683360B2 (en) 2017-07-03 2018-07-02 Targeted protein degradation
PCT/EP2018/067741 WO2019007869A1 (en) 2017-07-03 2018-07-02 TARGETED DEGRADATION OF PROTEINS
EP18735571.4A EP3649149A1 (en) 2017-07-03 2018-07-02 Targeted protein degradation
BR112019028024-3A BR112019028024A2 (pt) 2017-07-03 2018-07-02 método para controlar o nível de uma sequência de polipeptídeos, receptor de antígeno quimérico, proteína de fusão, polinucleotídeo isolado, vetor de expressão, célula, composição farmacêutica, e, método para engenheirar uma célula imunomodulatória.
GB1810814.2A GB2568987A (en) 2017-07-03 2018-07-02 Targeted protein degradation
US16/879,896 US11427643B2 (en) 2017-07-03 2020-05-21 Targeted protein degradation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1710620.4A GB201710620D0 (en) 2017-07-03 2017-07-03 Targeted protein degradation

Publications (1)

Publication Number Publication Date
GB201710620D0 true GB201710620D0 (en) 2017-08-16

Family

ID=59592357

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB1710620.4A Ceased GB201710620D0 (en) 2017-07-03 2017-07-03 Targeted protein degradation
GB1810814.2A Withdrawn GB2568987A (en) 2017-07-03 2018-07-02 Targeted protein degradation

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1810814.2A Withdrawn GB2568987A (en) 2017-07-03 2018-07-02 Targeted protein degradation

Country Status (8)

Country Link
US (2) US10683360B2 (enExample)
EP (1) EP3649149A1 (enExample)
JP (1) JP7369039B2 (enExample)
CN (1) CN110997710A (enExample)
BR (1) BR112019028024A2 (enExample)
CA (1) CA3068365A1 (enExample)
GB (2) GB201710620D0 (enExample)
WO (1) WO2019007869A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111107874A (zh) * 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
BR112020007576A2 (pt) * 2017-10-18 2020-09-24 Novartis Ag composições e métodos para degradação de proteína seletiva
US12049482B2 (en) * 2017-10-31 2024-07-30 The Brigham And Women's Hospital, Inc. Molecular switch-mediated control of engineered cells
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
EP3908329A4 (en) * 2019-01-07 2022-12-07 The Regents of the University of California CAGE DEGRON-BASED MOLECULAR FEEDBACK CIRCUITS AND METHODS OF USE THERE
KR20210112347A (ko) * 2019-01-07 2021-09-14 유니버시티 오브 워싱턴 단백질 분해의 조정 가능한 제어를 위한 단백질 스위치의 데노보 설계
CN111825769B (zh) * 2019-04-16 2022-03-25 上海科技大学 一种泛素化缺失的嵌合抗原受体及其用途
US20220251152A1 (en) * 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
AU2020391285B2 (en) * 2019-11-27 2024-05-23 Onegene Biotechnology Inc. Multifunctional multispecific multimeric biomolecule polymer having prolonged in-vivo duration
US20230114854A1 (en) * 2020-02-14 2023-04-13 Cellgentek Co., Ltd. Chimeric antigen receptor targeting b-cell maturation antigen and use thereof
CN114057890A (zh) * 2020-07-31 2022-02-18 南京北恒生物科技有限公司 新型共刺激结构域及其用途
CN116368152A (zh) * 2020-09-13 2023-06-30 山东博安生物技术股份有限公司 通过受体tac技术的膜结合蛋白的下调
CN112266404A (zh) * 2020-10-28 2021-01-26 北京大学深圳研究生院 选择性修饰靶标蛋白的基团转移方法及其应用
CN112940096A (zh) * 2021-01-29 2021-06-11 西安交通大学 一种膀胱癌血清多肽标志物及其应用
IL304904A (en) * 2021-02-01 2023-10-01 St Phi Therapeutics Co Ltd Target protein degradation system and its use
CN112980882A (zh) * 2021-03-15 2021-06-18 上海科技大学 Crbn基因在构建GSPT1敏感模型中的用途
NL2031325B1 (en) 2022-03-18 2023-09-29 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Novel zinc finger degron sequences
JP2025539386A (ja) 2022-12-01 2025-12-05 エー・テー・ハー・チューリッヒ 修飾アミノ酸デグロン（ｍａａｄ）を同定する方法
WO2025248464A2 (en) 2024-05-29 2025-12-04 Cell Control Biotherapeutics, Inc. Loop reinforcement expression system for improved cell therapy products
CN119699269B (zh) * 2024-07-10 2025-10-17 太原市中心医院 基于sbsn 600位赖氨酸发生二羟基异丁酰化修饰的用于银屑病研究的小鼠模型构建方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1417344B1 (en) * 2001-08-17 2011-06-15 Toolgen, Inc. Zinc finger domain libraries
CN103688176A (zh) * 2011-04-29 2014-03-26 细胞基因公司 利用cereblon作为预报因子治疗癌和炎性疾病的方法
EP2818480B1 (en) * 2012-02-24 2020-08-26 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same
CN103265635A (zh) * 2013-04-28 2013-08-28 中山大学附属第一医院 一种通用的靶向蛋白嵌合型分子化合物的构建方法
KR20250127179A (ko) * 2014-04-14 2025-08-26 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US20170306385A1 (en) * 2014-10-10 2017-10-26 Dana-Farber Cancer Institute, Inc. Methods for discovering therapeutics that alter the stability of target proteins
EP3331905B1 (en) * 2015-08-06 2022-10-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
EP3347712B1 (en) * 2015-09-11 2022-05-11 The Broad Institute, Inc. Methods of identifying drug-modulated polypeptide targets for degradation
US10830762B2 (en) * 2015-12-28 2020-11-10 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
ES2916335T3 (es) * 2016-10-20 2022-06-30 Celgene Corp Receptores de antígeno quimérico heterodimerizable basados en cereblon

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111107874A (zh) * 2017-09-14 2020-05-05 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗

Also Published As

Publication number Publication date
GB2568987A (en) 2019-06-05
CA3068365A1 (en) 2019-01-10
BR112019028024A2 (pt) 2020-07-07
US20190002578A1 (en) 2019-01-03
WO2019007869A1 (en) 2019-01-10
EP3649149A1 (en) 2020-05-13
JP2020529970A (ja) 2020-10-15
CN110997710A (zh) 2020-04-10
JP7369039B2 (ja) 2023-10-25
US11427643B2 (en) 2022-08-30
US20200283538A1 (en) 2020-09-10
US10683360B2 (en) 2020-06-16
GB201810814D0 (en) 2018-08-15

Similar Documents

Publication Publication Date Title
GB201810814D0 (en) Targeted protein degradation
IL275298B1 (en) Mitochondria-targeted peptides
GB201502305D0 (en) Protein
GB201502306D0 (en) Protein
IL273493A (en) Modified CAR-T
GB201820521D0 (en) n
GB201711481D0 (en) Protein purification
AU201714106S (en) Mandoline
SG11202003137SA (en) Conjugated-diene-based rubber
GB201800334D0 (en) Modified protein
IL272526A (en) Enhanced endoinulinase proteins
GB201701986D0 (en) n
ZA201800682B (en) Harvester
GB201813378D0 (en) n
PL3612182T3 (pl) Plaster zawierający rupatadynę
GB201522610D0 (en) Protein
GB201719520D0 (en) Neuroprotectvie peptide
NO20172003A1 (en) Use-and-throw-away horseshoe
GB201717266D0 (en) Armour Assembly
GB201707210D0 (en) Improved hitchlock
ZA202001317B (en) Pasteurizer
HUE052534T2 (hu) Hullámvasút
DK3351149T3 (en) Syltetøjsfontæne
GB2559738B (en) Animal tongue-tie
HUP1700207A2 (en) Thresher

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)